TCRX TSC-101 reports 79% 6-month relapse-free survival in post-HCT
TSC-101 in high-risk post-HCT patients showed 79% relapse-free survival at 6 months, with safety also reported in the heme program.
Prioritization is on in vivo TCR-T therapies for solid tumors, with IND-enabling studies progressing and preclinical data expected in early 2027.
In the heme program, TSC-101 showed promising relapse-free survival and safety in high-risk post-HCT patients.Original document: TScan Therapeutics, Inc…